Opinion|Videos|July 27, 2023
The Future of the NDMM: Comparing Emergent Regimens and Understanding Unmet Needs
Author(s)Luciano Costa, MD, PhD, Timothy Schmidt, MD
Dr. Costa and Dr. Schmidt consider promising emergent treatment options and current unmet needs in the NDMM treatment landscape.
Advertisement
Episodes in this series
Advertisement
Related to this article
Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.
Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.
The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.
“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.
Interim phase 2 data show a median PFS of 17.7 months with carotuximab plus apalutamide vs 2 months with apalutamide alone in metastatic CRPC.
Ahead of a fourth-quarter 2026 FDA decision, TALAPRO-3 investigators outline the testing, monitoring, and sequencing steps needed to adopt the regimen.
Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.
Melody Rasouli, MD, MBA, FACOG, explained how random-start ovarian stimulation and rapid sperm banking fit fertility preservation into cancer care.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
3
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
4
Considering Talquetamab and Emerging Bispecifics in R/R Multiple Myeloma
5